Search company, investor...

On-X Life Technologies

Founded Year



Acquired | Acquired



About On-X Life Technologies

On-X Life Technologies is a leading manufacturer of artifical heart valve replacement and repair products. On-X aortic and mitral prosthetic valves are FDA approved and have been safely implanted in approximately 200,000 patients worldwide. On-X mechanical heart valves are made with the most advanced material in the industry - pure pyrolytic carbon. The advanced design and materials make it the best lifelong heart valve replacement option available today.

Headquarters Location

1300 E. Anderson Lane Bldg B

Austin, Texas, 78752,

United States


Missing: On-X Life Technologies's Product Demo & Case Studies

Promote your product offering to tech buyers.

Reach 1000s of buyers who use CB Insights to identify vendors, demo products, and make purchasing decisions.

Missing: On-X Life Technologies's Product & Differentiators

Don’t let your products get skipped. Buyers use our vendor rankings to shortlist companies and drive requests for proposals (RFPs).

Expert Collections containing On-X Life Technologies

Expert Collections are analyst-curated lists that highlight the companies you need to know in the most important technology spaces.

On-X Life Technologies is included in 1 Expert Collection, including Medical Devices.


Medical Devices

3,383 items

Companies that received PMA from the FDA since 2014. Companies tagged as #FDAPMA

On-X Life Technologies Patents

On-X Life Technologies has filed 17 patents.

The 3 most popular patent topics include:

  • Cardiac surgery
  • Valvular heart disease
  • Annular solar eclipses
patents chart

Application Date

Grant Date


Related Topics




Cardiac anatomy, Valvular heart disease, Cardiac surgery, Implants (medicine), Syndromes


Application Date


Grant Date



Related Topics

Cardiac anatomy, Valvular heart disease, Cardiac surgery, Implants (medicine), Syndromes



Latest On-X Life Technologies News

$4.5+ Billion Artificial Heart Market Size to Exhibit CAGR of 15+% by 2028, Deep Dive Analysis of Key Players and Growth Opportunities

Oct 12, 2022

Global Artificial Heart Market: Competitive Landscape SynCardia Systems, LLC; BiVACOR Inc.; CARMAT; Cleveland Heart, Inc.; ABIOMED; ON-X LIFE TECHNOLOGIES INC.; Abbott; Cirtec; Thoratec Corporation; and MyLVAD are a few of the key players profiled during the study of the artificial heart market. Several other major companies were also analyzed to get a holistic view of the market and its ecosystem. According to the World Health Organization (WHO), the population aged 60 years and above is anticipated to rise from 900 million in 2015 to 2 billion in 2050. An increase in the geriatric population may lead to a surge in the incidence of age-related health problems, including cardiovascular diseases and respiratory diseases. The rise in prevalence of cardiovascular diseases can be associated with sedentary lifestyles; smoking, tobacco and alcohol consumption; and an unbalanced diet. An overall rise in the global burden of cardiovascular diseases, coupled with an increase in mortality rate among the geriatric population due to these diseases, is a key factor contributing to the growth of the artificial heart market. According to the (WHO), cardiovascular diseases account for ~17.9 million deaths every year, i.e., ~31% of the total death count reported worldwide. Thus, the surge in the overall prevalence of cardiovascular diseases boosts the growth of the artificial heart market. Inquiry Before Purchase: Impact of COVID-19 Pandemic on Global Artificial Heart Market: The emergence of COVID-19 compelled healthcare providers to deprioritize or postpone therapeutic procedures, which adversely affected the sales of cardiovascular devices, such as artificial hearts, especially in 2020. The study "The Impact of the COVID-19 Pandemic on Waiting Times for Elective Surgery Patients: A Multicenter Study," published in July 2021, stated that the incidence of elective procedures decreased rapidly after the onset of the first COVID-19 wave, in March 2020; nonetheless, there has been a recovery in May and June, after which the surgery incidence was 22% higher than that in the reference years. The pandemic and consequent social restrictions, and labor force shortage hampered the manufacturing of heart valves and related materials. Growing Prevalence of Cardiovascular Diseases and Rising Funding Support Fuel Artificial Heart Market Growth: North America dominated the artificial heart market with ~49% share in 2021. The market growth in the region is majorly attributed to the high prevalence of cardiovascular, neurological, and other diseases, and a surge in the geriatric population. Cost plays a notable role in the sale of artificial heart valves. Further, the COVID-19 pandemic adversely affected the care and services provided by hospitals for patients with heart conditions. The lockdowns imposed by various country governments hampered the manufacturing of heart valves. Quickly Purchase Premium Copy of Artificial Heart Market Growth Report (2022-2028) at: Browse Related Reports: Cardiac Prosthetic Devices Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by By Product (Annuloplasty Rings, Pacemaker Leads, Tissue patches, Ventricular Assist Device, Artificial Hearts, Prosthetic Heart Valves, Defibrillator Leads), and By End User (Hospitals, Ambulatory Care Centre and Others) and Geography Heart Pump Devices Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by Product (Ventricular Assist Devices, Intra-Aortic Balloon Pumps, and Total Artificial Heart), Type (Implantable Heart Pump Devices, and Extracorporeal Heart Pump Devices), Therapy (Bridge-To-Candidacy (BTC), Bridge-To-Transplant (BTT), Destination Therapy (DT), and Others), and Geography Cardiac Equipment Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by Type (Balloon Pumps, Cardiopulmonary bypass pumps, Cardiac Ultrasound devices, Implantable Cardioverter Defibrillator, Cardiac Resynchronization Therapy, Defibrillators Pacemakers, Ventricular Assist Devices, total Artificial Heart, Counter pulsation Devices.) Artificial Organs Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by Product (Artificial Heart, Artificial Kidney, Artificial Liver, Artificial Pancreas, Artificial Lungs, Others); Method of Fixation (Implantable, Externally Worn); Technology (Electronic, Mechanical) Heart Transplant Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Surgery Type (Ventricular Assist Devices, Total Artificial Hearts, others); End User (Hospital, Cardiac Institutes, others) Artificial Heart Stent Market Forecast to 2028 - COVID-19 Impact and Global Analysis by Product (Bare-Metal Stent (BMS), Drug-Eluting Stent (DES), Bioresorbable Vascular Scaffold (BVS)); Application (Acute Myocardial Infarction, Unstable Angina, Angina Pectoris); End User (Hospitals, Ambulatory Surgical Center, Others) Artificial Heart Lung Machine Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Type (Single Roller Pump, Double Roller Pump); Application (Cardiac Surgery, Lung Transplantation Operations, Acute Respiratory Failure Treatment, Others); End User (Hospital, Ambulatory Surgical Centers, Specialty Care Center) and Geography Cardiac Prosthetic Devices Market Forecast to 2028 - Covid-19 Impact and Global Analysis - by By Product (Annuloplasty Rings, Pacemaker Leads, Tissue patches, Ventricular Assist Device, Artificial Hearts, Prosthetic Heart Valves, Defibrillator Leads), and By End User (Hospitals, Ambulatory Care Centre and Others) and Geography Heart Blocks Treatment Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Product Type (First Degree Heart Block, Second Degree Heart Block, And Third Degree Heart Block. On the basis of treatment, the market is categorized as Pacemaker, Transcutaneous pacing (TCP), Follow-up electrophysiology study, Medication. On the basis of end use, the market is categorized as Hospitals, Homecare, Clinics), and Geography Heart Implant Device Market Forecast to 2028 - COVID-19 Impact and Global Analysis By Device (Pacemaker Devices, Coronary Stents, Implantable Cardioverter Defibrillator, Cardiac Resynchronization Therapy Devices, Hemodynamic Monitoring Devices); Application (Arrhythmias, Myocardial Ischemia, Acute Myocardial Infraction, Congestive Heart Failure, Others); End User (Hospitals, Emergency Medical Centers, Ambulatory Surgical Center, Home Care Settings, Others) and Geography About Us: The Insight Partners is a one stop industry research provider of actionable intelligence. We help our clients in getting solutions to their research requirements through our syndicated and consulting research services. We specialize in industries such as Semiconductor and Electronics, Aerospace and Defense, Automotive and Transportation, Biotechnology, Healthcare IT, Manufacturing and Construction, Medical Device, Technology, Media and Telecommunications, Chemicals and Materials. Contact Us: If you have any queries about this report or if you would like further information, please contact us: Contact Person: Sameer Joshi

On-X Life Technologies Frequently Asked Questions (FAQ)

  • When was On-X Life Technologies founded?

    On-X Life Technologies was founded in 1994.

  • Where is On-X Life Technologies's headquarters?

    On-X Life Technologies's headquarters is located at 1300 E. Anderson Lane, Austin.

  • What is On-X Life Technologies's latest funding round?

    On-X Life Technologies's latest funding round is Acquired.

  • Who are the investors of On-X Life Technologies?

    Investors of On-X Life Technologies include CryoLife, PTV Sciences, Paul Capital Partners and HealthCare Royalty Partners.

  • Who are On-X Life Technologies's competitors?

    Competitors of On-X Life Technologies include Solace Therapeutics, Dune Medical Devices, Censis Technologies, Paragon Medical, Cambridge Endoscopic Devices and 11 more.

Compare On-X Life Technologies to Competitors

NeuroLife Noninvasive Solutions

NeuroLife Noninvasive Solutions offers Surgical and medical Instruments and apparatus

Axis Surgical Technologies

Axis Surgical Technologies, Inc. aims to develop, manufacture, and market devices that improve quality and efficiency in spinal surgery, especially for minimally invasive surgical techniques. Based in Mountain View, California, Axis offers an integration of visualization and articulation capabilities and provides spinal surgery equipment. Axis' FDA Grant In March 2010, Axis announced that it received 510(k) clearance from the Food and Drug Administration to market its C-MOR„ Visualization Device to use in diagnostic and operative arthroscopic and endoscopic procedures. This portable tool provides visualization and illumination of an interior cavity through either a natural or surgical opening. The ergonomic lightweight device also offers practitioners the convenience of endoscopic visualization and efficient one-handed operating ability; this device can be employed in hospital outpatient departments, ambulatory surgery centers, and office surgery suites.


ClearMedical is a distributor of remanufactured brand name surgical devices. ClearMedical aims to drive cost savings by selling high-volume, disposable, FDA approved laparoscopic, arthroscopic, and general surgical devices at reduced prices. The company collects used Single-Use-Devices (SUDs) from hospitals, reprocesses them consistent with FDA approvals, and sells them to hospitals and surgery centers wanting to reduce supply acquisition costs. The company's device list includes harmonic scalpels from Ethicon, trocars from Ethicon, US Surgical (AutoSuture), laparoscopic instruments from Ethicon, US Surgical (AutoSuture), clip appliers from ethicon, US Surgical (AutoSuture), linear cutter and staplers from Ethicon, and bone shavers from Linvatec, Smith & Nephew, and Stryker.

Sierra Surgical Technologies

Sierra Surgical Technologies is a developer of minimally invasive surgical systems.


NeuroSonix is an Israeli medical device company targeting the market of cerebral embolic protection during cardiac surgical and other minimally invasive procedures. NeuroSonix has conceived, developed and patented a technology and medical devices for the prevention of acute cerebral embolism during open-heart cardiac surgery as well as other invasive and minimally-invasive procedures. The company's technology, which is based on ultrasound, aims to enable a non-invasive deflection of embolic material flowing inside the body, away from the cerebral arteries. This new ultrasonic modality aims to reduce the embolic load on the patient's brain. The first product developed by the company is the EmBlocker"ž, intended to provide protection from acute cerebral embolism during cardiac surgical procedures. The Protection Collar, the company's second product, is intended for embolic protection during minimally-invasive procedures and Cath-lab practice.

Cambridge Endoscopic Devices

Cambridge Endoscopic Devices (CED) has developed a line of surgical instruments that aim to address the need for enhanced dexterity and manipulation in laparoscopic and endoscopic surgery. Per the company, these instruments overcome surgical barriers encountered with traditional endoscopic and laparoscopic instruments, allowing for the potential of new surgical procedures and better, more cost effective clinical outcomes.

Discover the right solution for your team

The CB Insights tech market intelligence platform analyzes millions of data points on vendors, products, partnerships, and patents to help your team find their next technology solution.

Request a demo

CBI websites generally use certain cookies to enable better interactions with our sites and services. Use of these cookies, which may be stored on your device, permits us to improve and customize your experience. You can read more about your cookie choices at our privacy policy here. By continuing to use this site you are consenting to these choices.